atenolol has been researched along with natriuretic peptide, brain in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (84.62) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peuhkurinen, K; Risteli, J; Ruskoaho, H; Tokola, H; Uusimaa, P; Vuolteenaho, O; Ylitalo, A | 1 |
| Brown, MJ; Cockcroft, JR | 1 |
| Bang, LE; Devereux, RB; Fossum, E; Hall, C; Hildebrandt, P; Ibsen, H; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K | 1 |
| Bang, LE; Devereux, RB; Fossum, E; Hall, C; Hildebrandt, PR; Ibsen, H; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K | 1 |
| Asai, T; Fujita, H; Kanmatsuse, K; Kushiro, T | 1 |
| Dahlöf, B; Devereux, RB; Hall, C; Hildebrandt, PR; Ibsen, H; Kjeldsen, SE; Nielsen, OW; Olsen, MH; Wachtell, K; Wergeland, R | 1 |
| Dahlöf, B; Devereux, RB | 1 |
| Barba, J; Castellano, JM; Díez, J; González, A; López, B | 1 |
| Bell, D; Devine, AB; McDermott, BJ; Zhao, YY | 1 |
| Aronson, JK | 1 |
| Eguchi, K; Hoshide, S; Ishikawa, J; Kario, K; Matsui, Y; Pickering, TG; Shibasaki, S; Shimada, K | 1 |
| Chaturvedi, N; Hughes, AD; Mayet, J; O'Brien, E; Poulter, NR; Sever, PS; Sharp, A; Stanton, AV; Tapp, RJ; Thom, SA | 1 |
| Peuhkurinen, K; Peuhkurinen, S; Risteli, J; Uusimaa, P; Vuolteenaho, O; Ylitalo, A | 1 |
1 review(s) available for atenolol and natriuretic peptide, brain
| Article | Year |
|---|---|
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Atrial Natriuretic Factor; Biomarkers; Blood Pressure; Cardiovascular Agents; Cohort Studies; Drug Utilization; Endothelium, Vascular; Follow-Up Studies; Heart Atria; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Models, Biological; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Precursors; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Stroke; Thrombosis; Treatment Outcome | 2007 |
6 trial(s) available for atenolol and natriuretic peptide, brain
| Article | Year |
|---|---|
N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.
Topics: Aged; Anti-Infective Agents; Atenolol; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Stroke; Ultrasonography | 2004 |
Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy.
Topics: Aged; Atenolol; Atrial Natriuretic Factor; Blood Pressure; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments | 2005 |
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albumins; Antihypertensive Agents; Atenolol; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Creatinine; Endpoint Determination; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; ROC Curve; Scandinavian and Nordic Countries | 2006 |
Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension.
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atenolol; Biomarkers; Blood Pressure; Cytokines; Diastole; Female; Heart Ventricles; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Systole; Ultrasonography | 2007 |
Monitoring of the central pulse pressure is useful for detecting cardiac overload during antiadrenergic treatment: the Japan Morning Surge 1 study.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Biomarkers; Blood Pressure; Blood Pressure Determination; Brachial Artery; Carotid Arteries; Case-Control Studies; Doxazosin; Drug Therapy, Combination; Female; Humans; Hypertension; Japan; Male; Middle Aged; Natriuretic Peptide, Brain | 2008 |
Natriuretic peptides and collagen biomarkers in patients with medical treatment for hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Atrial Natriuretic Factor; Biomarkers; Collagen; Collagen Type I; Humans; Hypertension; Natriuretic Peptide, Brain; Peptide Fragments; Peptides; Procollagen; Ventricular Remodeling | 2011 |
6 other study(ies) available for atenolol and natriuretic peptide, brain
| Article | Year |
|---|---|
Vasoactive peptides and procollagen propeptides in patients with hypertension in relation to cardiac hypertrophy and diastolic heart failure: design of the study and patient characteristics.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Atrial Natriuretic Factor; Bendroflumethiazide; Cardiomegaly; Endothelin-1; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Perindopril; Procollagen; Randomized Controlled Trials as Topic | 2001 |
Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Humans; Losartan; Natriuretic Peptide, Brain | 2002 |
Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atenolol; Blood Pressure; Cardiomegaly; Doxazosin; Drug Therapy, Combination; Echocardiography; Heart Rate; Hypertension; Losartan; Male; Natriuretic Peptide, Brain; Rats; Rats, Inbred SHR; RNA, Messenger | 2005 |
Influence of atenolol and nifedipine on nitric-oxide deficient cardiomyocyte hypertrophy and expression of the cardio-endocrine peptide intermedin and its receptor components.
Topics: Adrenomedullin; Animals; Atenolol; Atrial Natriuretic Factor; Blood Pressure; Endothelin-1; Gene Expression Regulation; Hypertrophy; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Myocytes, Cardiac; Natriuretic Peptide, Brain; Neuropeptides; NG-Nitroarginine Methyl Ester; Nifedipine; Nitric Oxide; Oxidative Stress; Peptides; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptor Activity-Modifying Protein 1; Receptor Activity-Modifying Protein 2; Receptor Activity-Modifying Protein 3; Receptor Activity-Modifying Proteins; Receptors, Cell Surface; Systole | 2008 |
Changing beta-blockers in heart failure: when is a class not a class?
Topics: Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Carbazoles; Carvedilol; Heart; Heart Failure; Humans; Natriuretic Peptide, Brain; Propanolamines | 2008 |
Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Diastole; Echocardiography, Doppler; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Ventricular Function, Left | 2010 |